Secondary arterial hypertension , definition,causes, pathophysiology, symptoms, diagnosis, differential diagnosis, treatment with doses
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive material from Harrison's and the NKF Primer. Let me compile a thorough, well-structured response.
Secondary Arterial Hypertension
Definition
Secondary arterial hypertension is hypertension associated with a specific, identifiable anatomic or biochemical cause — and is therefore potentially curable if that cause is removed or corrected. This distinguishes it from primary (essential) hypertension, which has no single identifiable cause.
Secondary hypertension accounts for approximately 10% of all hypertension in adults. Among children, secondary causes are the rule rather than the exception — up to 90% of young children with hypertension have an identifiable secondary cause.
When to suspect secondary hypertension:
- Treatment-resistant hypertension (BP uncontrolled on ≥3 drugs)
- Abrupt onset or worsening of hypertension
- Hypertension in patients <30 years
- Disproportionate target-organ damage for the level of BP
- Unprovoked hypokalemia, proteinuria, or LV hypertrophy on workup
— Harrison's Principles of Internal Medicine 22E, p. 2179
Causes
The main causes in approximate order of prevalence in adults:
| Cause | Estimated Prevalence Among Hypertensives |
|---|---|
| Obstructive Sleep Apnea (OSA) | Most common; >30% of hypertensives |
| Medication/substance-induced | Very common; >26% use NSAIDs alone |
| Renal parenchymal disease (CKD) | ~5% of non-OSA secondary HTN |
| Primary aldosteronism | 5–10% of all hypertensives; ~20% of resistant HTN |
| Renovascular disease (RAS) | 1–5% |
| Pheochromocytoma/Paraganglioma | Rare; 2–8 per million/year |
| Coarctation of the aorta | Uncommon in adults |
| Cushing syndrome | Uncommon |
| Thyroid disorders (hypo/hyperthyroidism) | Uncommon |
Drug/substance causes include:
- NSAIDs, oral contraceptives, systemic corticosteroids
- Amphetamines, cocaine, MDMA, cannabis
- Angiogenesis inhibitors (bevacizumab, sunitinib, sorafenib)
- Cyclosporine, tacrolimus, erythropoietin
- MAOIs, decongestants, antipsychotics
- Herbal agents: ephedra (Ma-Huang), licorice, ginseng, guarana, arnica, St. John's wort
— NKF Primer on Kidney Diseases 8e, p. 698; Harrison's 22E, p. 2181
Pathophysiology by Cause
1. Obstructive Sleep Apnea
Repeated episodes of upper-airway obstruction cause intermittent hypoxia → sympathetic nervous system activation → increased peripheral vascular resistance and BP. Abnormalities of the RAAS and fluid redistribution also contribute. BP elevation correlates directly with OSA severity.
2. Renal Parenchymal Disease (CKD)
Any CKD etiology can cause hypertension. ~75% of patients with GFR <45 mL/min are hypertensive. Mechanisms:
- Sodium and water retention (reduced GFR)
- RAAS activation (renal ischemia signals)
- Proteinuria independently increases sodium retention and BP
Glomerular diseases tend to produce hypertension at higher GFRs than interstitial diseases.
3. Renovascular Hypertension (Renal Artery Stenosis)
Two main types:
- Atherosclerotic RAS (ARAS): >90% of cases. Unilateral lesions near the origin of the renal artery. Older patients with widespread ASCVD.
- Fibromuscular Dysplasia (FMD): <10% of cases. Younger women. Distal artery involvement with classic "string of beads" angiographic appearance.
Mechanism: Renal ischemia → renin release → angiotensin II–mediated vasoconstriction and aldosterone secretion → hypertension and sodium retention. In unilateral disease, the contralateral kidney compensates with pressure natriuresis. In bilateral disease, sodium retention dominates and renin may be paradoxically normal/low. A stenosis typically requires >70% luminal narrowing to become hemodynamically significant.
4. Primary Aldosteronism
Caused by bilateral adrenal hyperplasia (~60%) or unilateral aldosterone-producing adenoma (~40%). Somatic mutations in KCNJ5 (inwardly rectifying K⁺ channel) allow Na⁺ influx → chronic membrane depolarization → Ca²⁺ influx → aldosterone hypersecretion.
Aldosterone excess → renal Na⁺ retention → volume expansion → BP elevation + suppressed renin + hypokalemia (via K⁺ excretion).
5. Pheochromocytoma / Paraganglioma (PPGL)
Tumors of adrenomedullary chromaffin cells (pheo) or extraadrenal sympathetic ganglia (paraganglioma) secrete epinephrine, norepinephrine, or dopamine → severe hypertension via α₁-receptor–mediated vasoconstriction. Episodic catecholamine release causes paroxysmal hypertension.
6. Coarctation of the Aorta
Constriction of the descending thoracic aorta (usually distal to the left subclavian artery) → mechanical obstruction → increased BP in upper extremities + reduced perfusion to kidneys → RAAS activation → further BP elevation.
7. Cushing Syndrome
Glucocorticoid excess → sodium retention (through mineralocorticoid receptor activation), increased angiotensinogen, potentiation of vasopressor responses.
8. Thyroid Disorders
- Hypothyroidism: Increased peripheral vascular resistance (loss of thyroid-mediated vasodilation), decreased heart rate → diastolic hypertension predominant
- Hyperthyroidism: Increased cardiac output, decreased peripheral vascular resistance → systolic hypertension predominant
— Harrison's 22E, pp. 2180–2183; NKF Primer 8e, pp. 700–706
Symptoms
Most patients with secondary hypertension are asymptomatic from hypertension itself. Symptoms are often clues to the underlying cause:
| Cause | Symptoms/Signs |
|---|---|
| OSA | Snoring, daytime sleepiness, nocturnal gasping/choking, obesity, crowded oropharynx |
| Renovascular (FMD) | Young woman, abrupt-onset or resistant hypertension, abdominal bruit |
| Renovascular (ARAS) | Older patient, diffuse atherosclerosis, abdominal bruit, flash pulmonary edema |
| Primary aldosteronism | Muscle weakness, cramps, polyuria/nocturia (from hypokalemia), atrial fibrillation |
| Pheochromocytoma | Classic triad: episodic headache, palpitations, diaphoresis; pallor, paroxysmal BP spikes |
| Cushing syndrome | Weight gain (central obesity), moon face, buffalo hump, striae, glucose intolerance |
| Hypothyroidism | Fatigue, cold intolerance, constipation, bradycardia, dry skin |
| Hyperthyroidism | Heat intolerance, weight loss, palpitations, tremor, tachycardia |
| Coarctation of aorta | BP discrepancy arms > legs, weak femoral pulses, young patient, bicuspid aortic valve |
| CKD | Fatigue, hematuria, proteinuria (foamy urine), edema, elevated creatinine |
Diagnosis
Initial Evaluation (All Suspected Secondary HTN)
- Serum electrolytes, creatinine, eGFR, urinalysis with microscopy and protein-to-creatinine ratio
- Fasting glucose, lipid panel
- ECG, echocardiogram for LVH
- Thyroid function tests (TSH)
Specific Screening Tests by Cause
| Cause | Screening Test | Confirmatory Test |
|---|---|---|
| OSA | Epworth Sleepiness Scale, overnight oximetry | Polysomnography (gold standard) |
| Renal parenchymal disease | Urinalysis, creatinine, eGFR | Renal ultrasound, CT, renal biopsy (if glomerulonephritis suspected) |
| Renovascular (RAS) | Renal duplex ultrasound | CTA or MRA (preferred non-invasive); renal angiography (gold standard) |
| Primary aldosteronism | Plasma aldosterone/renin ratio (high ratio + high aldosterone) | Saline suppression test, captopril challenge; adrenal vein sampling (gold standard for lateralization) |
| Pheochromocytoma | 24-h urinary fractionated metanephrines or plasma free metanephrines | MIBG scintigraphy; CT/MRI of adrenals |
| Cushing syndrome | 24-h urinary free cortisol or late-night salivary cortisol | Low-dose dexamethasone suppression test; 24-h UFC |
| Coarctation of aorta | BP in arms vs. legs (gradient >20 mmHg), chest X-ray (rib notching) | CT or MR angiography; echocardiography |
| Thyroid disorder | TSH, free T4 | — |
— NKF Primer 8e, pp. 700–716; Harrison's 22E, pp. 2179–2183
Differential Diagnosis
Secondary hypertension must be distinguished from primary (essential) hypertension and from each other:
- Primary HTN: No identifiable cause; gradual onset; family history; responds to standard therapy; no biochemical red flags
- White-coat hypertension: Elevated office BP, normal ambulatory monitoring
- Pseudohypertension: False elevation due to stiff arteries (elderly); confirmed by intra-arterial measurement
- Pseudopheochromocytoma: Labile/paroxysmal HTN without biochemical evidence of catecholamine excess; includes panic disorder, sympathomimetic drug use, alcohol withdrawal, hyperthyroidism, baroreflex failure, carcinoid syndrome
- Neurogenic HTN: Raised intracranial pressure (Cushing reflex), brain tumors
Treatment
Treatment is directed at the underlying cause whenever possible, with antihypertensive drug therapy as adjunct or primary management when the cause cannot be cured.
1. Obstructive Sleep Apnea
- CPAP (continuous positive airway pressure): first-line; BP reduction is modest (~3/2 mmHg on average but greater with resistant HTN, AHI >30, and good adherence ≥4 h/night)
- Lifestyle: weight loss (most effective), alcohol avoidance, sleep-position modification
- Antihypertensive agents: beta-blockers (evidence suggests particular efficacy), spironolactone (targets volume/aldosterone component)
2. Renal Parenchymal Disease (CKD)
- ACE inhibitors or ARBs: first-line (reduce proteinuria and slow CKD progression)
- Diuretics: Thiazide/thiazide-like (chlorthalidone 12.5–25 mg/day effective even in advanced CKD); loop diuretics for GFR <30 mL/min
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): reduce BP, proteinuria, and CKD progression
- Finerenone (nonsteroidal MRA): additional BP reduction in advanced CKD
- Target BP: <130/80 mmHg; often requires ≥3 agents
3. Renovascular Hypertension
Fibromuscular Dysplasia:
- Percutaneous transluminal angioplasty (PTA): first-line, preferred; achieves cure in 26–54% depending on FMD subtype; stenting rarely needed
- If surgery required: surgical reconstruction for complex lesions
- Medical therapy (if PTA declined): ACE inhibitor or ARB + low-dose aspirin
- Screen for extrarenal FMD: one-time head-to-pelvis CT/MR angiography
Atherosclerotic RAS:
- Medical therapy preferred (RCTs show no benefit of PTA over medical therapy for BP or renal preservation)
- ACE inhibitor or ARB (caution with bilateral RAS or solitary kidney — monitor creatinine/K⁺)
- Statins, antiplatelet therapy, and risk-factor control (same as other ASCVD)
- PTA considered only for recurrent flash pulmonary edema or progressive renal failure
4. Primary Aldosteronism
Unilateral adenoma:
- Laparoscopic unilateral adrenalectomy (procedure of choice)
- Preoperative preparation: spironolactone to normalize K⁺ and BP
- Cure of hypertension more likely if: age <50, BMI <26, duration <5 years, ≤2 antihypertensives, normal renal function
Bilateral hyperplasia (or surgery declined):
- Spironolactone 25–150 mg/day (start 25 mg/day, titrate) — first-line MRA
- Eplerenone (if spironolactone intolerated) — use 2:1 dose ratio with twice-daily dosing
- Amiloride — useful alternative if MRAs not tolerated
- Thiazide diuretics as add-on (monitor K⁺ carefully)
- Calcium channel blockers also effective for BP control
5. Pheochromocytoma / Paraganglioma
- Surgical resection (laparoscopic adrenalectomy): definitive treatment
- Preoperative preparation (essential — minimum 10–14 days):
- Alpha-blockade first: phenoxybenzamine (non-selective, irreversible) 10 mg BID, titrate to 20–40 mg BID; or doxazosin 2–16 mg/day; or prazosin 1–5 mg TID
- Beta-blockade second (only AFTER alpha-blockade to avoid hypertensive crisis from unopposed alpha stimulation): propranolol 20–40 mg TID or metoprolol 25–50 mg BID
- High-sodium diet + adequate hydration (prevent post-op hypotension)
- For inoperable/malignant disease: metyrosine (tyrosine hydroxylase inhibitor), chemotherapy (cyclophosphamide/vincristine/dacarbazine), MIBG therapy
6. Coarctation of the Aorta
- Percutaneous balloon angioplasty ± stenting: preferred in adults for localized CoA
- Surgery: reserved for complex lesions not amenable to percutaneous approach
- Proceed when translesional gradient >20 mmHg on angiography
- Antihypertensive therapy pre/post-procedure: ACE inhibitors, ARBs, beta-blockers
7. Cushing Syndrome
- Surgical resection of causative lesion (pituitary adenoma via transsphenoidal surgery for Cushing disease; adrenalectomy for adrenal adenoma; removal of ectopic ACTH source)
- Medical: ketoconazole 400–1200 mg/day, metyrapone 500–3000 mg/day, pasireotide (for Cushing disease), or mifepristone (for glucose intolerance/DM)
- Antihypertensives as adjunct
8. Thyroid Disorders
- Hypothyroidism: levothyroxine replacement (1.6 mcg/kg/day, titrate to normal TSH) — BP usually normalizes
- Hyperthyroidism: thionamides (methimazole 5–30 mg/day or propylthiouracil 50–150 mg TID), radioactive iodine, or surgery; beta-blockers (propranolol 40–160 mg/day) for symptomatic control
9. Drug-Induced Hypertension
- Identify and discontinue or substitute the offending agent
- If continuation required (e.g., anti-VEGF therapy for cancer): add antihypertensive therapy; treatment continues unless BP is uncontrollable or severe renal injury develops
Sources:
- Harrison's Principles of Internal Medicine 22E (2025), pp. 2179–2183
- NKF Primer on Kidney Diseases 8e, pp. 698–716
Nutrition in hypertension.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive, well-sourced material. Here is the full compiled response:
Nutrition in Hypertension
Dietary modification is a cornerstone of hypertension prevention and management, both as standalone therapy for elevated/stage 1 BP and as an adjunct to drug therapy in higher stages. Nutritional interventions target multiple mechanisms — sodium-volume balance, vascular tone, insulin sensitivity, and sympathetic activity.
1. Overall Dietary Patterns
The DASH Diet (Dietary Approaches to Stop Hypertension)
The DASH diet is the most rigorously studied and most effective single dietary pattern for BP reduction.
Composition:
- High in: fruits, vegetables, whole grains, low-fat dairy products, legumes, nuts, lean protein
- Low in: saturated fat, total fat, cholesterol, red meat, sweets, and sugar-sweetened beverages
- Targets potassium intake of 4700 mg/day, calcium ~1250 mg/day, and magnesium ~500 mg/day
BP Effects:
- Original 8-week feeding trial: ↓ SBP/DBP by 5.5/3.0 mmHg vs. typical US diet
- In behavior-change trials: ↓ SBP ~4 mmHg, DBP ~0.6 mmHg vs. advice-only
- With good adherence: expected SBP reduction of ~5 mmHg in hypertensive patients and 2–3 mmHg in normotensive individuals
- Particularly effective in African Americans and in those with pre-existing hypertension
- Greatest overall BP reduction among all tested dietary patterns (meta-analysis: ↓ SBP 7.6 mmHg, ↓ DBP 4.2 mmHg)
- BP improvement can occur without weight loss or sodium restriction, though combining these amplifies results
DASH + Sodium Restriction:
- Combining DASH with 2400 mg sodium/day: additional reduction of 7/4 mmHg
- DASH + low sodium diet in patients with SBP ≥150 mmHg: SBP reduction of up to ~20.8 mmHg
— Fuster and Hurst's The Heart 15e, p. 222; NKF Primer on Kidney Diseases 8e, p. 700; Harrison's 22E, p. 2184
Mediterranean Diet
- Rich in extra-virgin olive oil (monounsaturated fatty acids), vegetables, legumes, nuts, fruits, seafood; low in saturated fat and red meat; moderate red wine
- Consistently associated with reduced CVD and BP
- PREDIMED trial: reduced composite of MI, stroke, and CV death vs. low-fat diet over 4.8 years
- Also reduces inflammation, hepatic steatosis, T2D progression, and MetS
- Recommended as a rational alternative dietary pattern for cardiometabolic risk reduction
Other Dietary Patterns
- Low-carbohydrate diets, vegetarian/vegan diets: also show consistent BP-lowering effects in trials
2. Sodium (Salt) Restriction
Mechanism: Excess dietary sodium → increased plasma volume → elevated cardiac output and peripheral resistance → higher BP. Sodium also increases vascular stiffness and blunts arterial baroreceptor sensitivity.
Evidence:
- The INTERMAP study confirmed: higher dietary sodium and higher Na⁺/K⁺ ratio are directly associated with BP
- Dose-response relationship: any reduction in sodium intake produces BP benefit
- Sodium reduction of ~25% → SBP ↓ ~5 mmHg in hypertensive, 2–3 mmHg in normotensive adults
- Long-term sodium reduction (10–15 year follow-up): 30% reduction in new-onset CVD events
Targets:
- Recommended: <2300 mg sodium/day (<100 mmol/day; equivalent to ~6 g NaCl)
- More aggressive target: <1500 mg/day (especially in Black patients, CKD, or older adults)
- Expected SBP reduction: 2–8 mmHg
Practical strategies:
- Read food labels — in the US, >80% of sodium comes from processed/commercially prepared foods; only ~10% from naturally occurring sources
- Avoid high-sodium processed foods, fast foods, canned soups, deli meats, condiments
- Prepare meals at home using fresh ingredients
- Use herbs and spices instead of table salt
- Salt substitutes (replacing ~25% of NaCl with KCl): in a large Chinese RCT, reduced stroke by 14%, CVD events by 13%, all-cause mortality by 12%
— Harrison's 22E, pp. 2184–2185; NKF Primer 8e, p. 698
3. Potassium
Mechanism: Potassium promotes renal sodium excretion (natriuresis), reduces peripheral vascular resistance, and counteracts the vasoconstrictive effects of sodium.
Evidence:
- Potassium intake is inversely and dose-dependently associated with BP and stroke risk
- Meta-analyses: potassium supplementation (diet or pill) → SBP ↓ ~5 mmHg in hypertensive, ~2 mmHg in normotensive adults
- Benefit is ~3× greater in Black adults than White adults
- Greater BP reduction when background sodium intake is high (reflecting natriuretic synergy)
- Dose-response: optimal supplemental intake ~1200 mg/day (U-shaped curve)
Recommended intake:
- Men: 3400 mg/day; Women: 2600 mg/day (US Adequate Intake)
- DASH diet provides 4700 mg/day
High-potassium foods: bananas, oranges, avocados, potatoes, sweet potatoes, tomatoes, spinach, legumes, low-fat dairy
Contraindications to supplementation: hyperkalemia, advanced CKD (eGFR <30), use of potassium-sparing diuretics, RAAS inhibitors, or MRAs (spironolactone, eplerenone, finerenone)
— Harrison's 22E, pp. 2185–2186
4. Weight Reduction
Mechanism: Obesity activates the RAAS, increases sympathetic activity, promotes sodium retention, and induces insulin resistance — all raising BP.
Evidence:
- Direct dose-response: ~1 mmHg SBP reduction per kilogram of weight lost
- Behavioral weight-loss programs (6–12 months): average loss ~10 lb (4.5 kg) → SBP ↓ ~5 mmHg
- Weight loss also improves lipids and reduces risk of T2D
Target: BMI 18.5–24.9 kg/m²; any weight reduction is beneficial
Expected SBP reduction: 5–20 mmHg per 10-kg weight loss
Approach:
- Combined calorie restriction + increased physical activity
- Behavioral counseling (most sustainable)
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) — FDA approved for weight loss, also reduce BP
- SGLT2 inhibitors — modest BP reduction (off-label for weight, approved for T2D/CKD/HF)
- Bariatric surgery: for BMI ≥40 or ≥35 with comorbidities
— Harrison's 22E, p. 2185; NKF Primer 8e, p. 698
5. Alcohol Restriction
Mechanism: Alcohol activates the sympathetic nervous system, increases cortisol, and has direct vasopressor and cardiac effects. The relationship is roughly linear with no safe threshold.
Recommended limits:
- Men: ≤2 standard drinks/day
- Women: ≤1 standard drink/day
- Expected SBP reduction: 2–4 mmHg
6. Other Micronutrients
| Nutrient | Effect on BP | Evidence |
|---|---|---|
| Calcium | High calcium diet associated with modest BP reduction; dairy-based preferred | Variable; DASH diet provides adequate calcium |
| Magnesium | Some evidence of modest BP reduction; deficiency associated with higher BP | Inconsistent trial data |
| Fish oil (omega-3) | Modest BP reduction, especially at higher doses (≥3 g/day EPA+DHA) | Supported; also reduces CVD risk |
| Garlic | Some evidence of modest BP reduction | Limited robust trial data |
| Fiber | Higher dietary fiber associated with lower BP | Epidemiologic support; part of DASH |
| Caffeine | Short-term BP elevation; chronic regular use — tolerance develops | Avoid in uncontrolled hypertension |
Potassium, magnesium, and calcium supplementation via diet (rather than pills) is preferred, as dietary sources deliver a broader range of beneficial nutrients and naturally reduce sodium intake.
— NKF Primer 8e, p. 698; Harrison's 22E, p. 2186
7. Summary: Expected BP Reductions by Lifestyle Modification
| Intervention | Recommendation | Expected ↓ SBP |
|---|---|---|
| Weight reduction | BMI 18.5–24.9 | 5–20 mmHg per 10 kg lost |
| DASH diet | Rich in fruits, vegetables, low-fat dairy; low in saturated fat | 8–14 mmHg |
| Dietary sodium reduction | <2300 mg/day (ideally <1500 mg/day) | 2–8 mmHg |
| Potassium supplementation | 3400–4700 mg/day via diet | ~5 mmHg |
| Aerobic exercise | ≥150 min/week (brisk walking, swimming) | 5–8 mmHg |
| Dynamic resistance exercise | 3×/week, 6 exercises | ~4 mmHg |
| Isometric exercise (handgrip) | 4 × 2 min, 3×/week, 8–10 weeks | ~5 mmHg |
| Alcohol moderation | ≤2 drinks/day (men); ≤1 (women) | 2–4 mmHg |
These effects are additive — combining multiple lifestyle interventions can achieve BP reductions comparable to a single antihypertensive drug (~10–15 mmHg), making them highly clinically meaningful, particularly for stage 1 hypertension and as adjuncts to pharmacotherapy.
— NKF Primer on Kidney Diseases 8e, Table 64.9, p. 700; Harrison's Principles of Internal Medicine 22E, Table 288-2, p. 2184; Fuster and Hurst's The Heart 15e, pp. 222–223
Nutrition in hypertension.
I just covered this topic in detail in my previous response. Here's a quick summary of what was included:
Topics covered:
- DASH Diet — composition, BP effects (↓ SBP 5–14 mmHg), combining with sodium restriction (↓ up to ~20.8 mmHg in severe HTN)
- Mediterranean Diet — evidence, cardiometabolic benefits
- Sodium restriction — mechanism, target <2300 mg/day, practical strategies, salt substitutes (↓ stroke 14%, CVD 13%)
- Potassium — mechanism, recommended intake 3400–4700 mg/day, ↓ SBP ~5 mmHg, contraindications
- Weight reduction — ~1 mmHg per kg lost, GLP-1 agonists, SGLT2 inhibitors
- Alcohol restriction — ≤2 drinks/day men, ≤1 women, ↓ SBP 2–4 mmHg
- Micronutrients — calcium, magnesium, omega-3, fiber, caffeine
- Summary table of all interventions with expected SBP reductions
You can scroll up to read the full detailed answer. Would you like me to expand on any specific aspect — for example, nutrition in hypertension with CKD, diabetes, or pregnancy?
This is a shared conversation. Sign in to Orris to start your own chat.